Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome
- PMID: 14579938
- DOI: 10.5414/cnp60242
Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome
Abstract
Background: Growing evidence shows that steroid-sensitive nephrotic syndrome (SSNS) is the result of a primary T-cell disturbance and leads to secondary anatomical and functional, however, not to immunological glomerular changes. In addition, immunoglobulin abnormalities in SSNS indicate a role of B-cell involvement.
Patients and methods: We therefore analyzed T- and B-cell activation markers in children with SSNS at different stages of the disease including different treatment regimens by measuring the soluble IL-2 receptor (sCD25) and the soluble low-affinity IgE receptor (sCD23), respectively. Seventy-five patients with SSNS (median age 8.0, range 2.5 - 18 years) were studied, 33 in relapse (RL) including 21 patients relapsing during alternate-day steroids (RL-SD). Forty-two patients were studied in remission (RM; 14 off treatment and 28 on alternate-day steroids (RM-AD)) and 22 age-matched children served as controls.
Results: Serum concentrations of sCD25 were increased in RL (113.6 +/- 19.5 micromol/l) compared to RM (79.8 +/- 8 micromol/l, p < 0.02) and controls (74.8 +/- 0.9 micromol/l, p < 0.02). Patients with RL-SD did not have elevated sCD25. In relapse, sCD25 was inversely correlated with age (R = -0.36, p < 0.04) and positively correlated with total IgG (R = 0.37, p < 0.04). Urinary excretion of sCD25 was also significantly elevated in RL of SSNS compared to RM and controls (71.2 +/- 11.9 micromol/g creatinine vs. 39.1 +/- 4.8 and 32.0 +/- 4.2 micromol/g, p < 0.05). Serum levels of sCD 23 were significantly elevated in RL (6.22 +/- 0.65 microg/l) compared to RM (3.1 +/- 0.83 microg/l, p < 0.02) and to controls (3.4 +/- 0.93 microg/l). The highest values, however, were found in RL-SD (7.8 +/- 1.7 microg/l) vs. untreated RL (p < 0.007) and RM-AD (p < 0.002). In untreated RL there was a significant correlation of sCD23 and total IgE (R = 0.67, p < 0.02) and in RL-SD with total IgG (R = 0.45, p < 0.05). sCD23 and sCD25 were not correlated with each other.
Conclusion: These data document parallel abnormalities of both CD23-mediated B as well as CD25-mediated T-cell activation and suggest that SSNS is not solely a disorder of T-cell dysfunction.
Similar articles
-
Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome.Pediatr Nephrol. 2002 Jun;17(6):413-7. doi: 10.1007/s00467-001-0817-7. Pediatr Nephrol. 2002. PMID: 12107805
-
CD19 + CD23+ B cells, CD4 + CD25+ T cells, E-selectin and interleukin-12 levels in children with steroid sensitive nephrotic syndrome.Ital J Pediatr. 2013 Jul 6;39:42. doi: 10.1186/1824-7288-39-42. Ital J Pediatr. 2013. PMID: 23830064 Free PMC article.
-
T-lymphocyte activation in steroid-sensitive nephrotic syndrome in childhood.Nephrol Dial Transplant. 1995;10(8):1348-52. Nephrol Dial Transplant. 1995. PMID: 8538925 Clinical Trial.
-
Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.Arch Dis Child. 2016 Apr;101(4):404-8. doi: 10.1136/archdischild-2015-308924. Epub 2015 Aug 19. Arch Dis Child. 2016. PMID: 26289063 Review.
-
An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome.Pediatr Nephrol. 2022 Sep;37(9):1957-1965. doi: 10.1007/s00467-021-05401-4. Epub 2022 Jan 10. Pediatr Nephrol. 2022. PMID: 35006356 Free PMC article. Review.
Cited by
-
Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Biomed Rep. 2016 Aug;5(2):237-242. doi: 10.3892/br.2016.711. Epub 2016 Jun 30. Biomed Rep. 2016. PMID: 27446549 Free PMC article.
-
Rituximab efficiency in children with steroid-dependent nephrotic syndrome.Pediatr Nephrol. 2010 Jun;25(6):1109-15. doi: 10.1007/s00467-010-1465-6. Epub 2010 Mar 18. Pediatr Nephrol. 2010. PMID: 20238230 Clinical Trial.
-
High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone.Pediatr Nephrol. 2008 Jul;23(7):1107-13. doi: 10.1007/s00467-008-0782-5. Epub 2008 Mar 7. Pediatr Nephrol. 2008. PMID: 18324419 Clinical Trial.
-
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?Pediatr Nephrol. 2007 Jun;22(6):893-8. doi: 10.1007/s00467-006-0427-5. Epub 2007 Feb 20. Pediatr Nephrol. 2007. PMID: 17310362
-
The role of the immune system in idiopathic nephrotic syndrome.Mol Cell Pediatr. 2021 Nov 18;8(1):18. doi: 10.1186/s40348-021-00128-6. Mol Cell Pediatr. 2021. PMID: 34792685 Free PMC article. Review.